Statement: the primary trial and the secondary trial have entirely different adverse event profiles.
Primary_evidence: Adverse Events 1:   Total: 28/36 (77.78%)   Lymphocytopenia 210/36 (27.78%)   Neutropenia 29/36 (25.00%)   Anemia 26/36 (16.67%)   Thrombocytopenia 24/36 (11.11%)   Hyperglycemia 27/36 (19.44%)   Nausea 213/36 (36.11%)   Diarrhea 211/36 (30.56%)   Fatigue 215/36 (41.67%)   Flu-like symptoms 26/36 (16.67%)   Hot Flashes 25/36 (13.89%)   AST/ALT elevation 211/36 (30.56%)   Arthralgia 24/36 (11.11%)
Secondary_evidence: Adverse Events 1:   Total: 1/22 (4.55%)   Blood bilirubin increased 1/22 (4.55%)   Alkaline phosphatase increased 1/22 (4.55%)